The Effect of Amiloride and Spironolactone in Healthy Persons
Information source: Holstebro Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: High Blood Pressure
Intervention: Amiloride (Drug); Spironolactone (Drug); Placebo (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Holstebro Hospital
Summary
This study will investigate whether retaining potassiom in the body will lead to changes in
blood pressure and changes in blood and urine samples.
Clinical Details
Official title: The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-Blinded, Randomised, Placebo-Controlled, Cross-Over Study
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment
Primary outcome: Blood pressure
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy
- Non-smokers
Exclusion Criteria:
- Smoking
- Under medical treatment
Locations and Contacts
Medical Research, Holstebro 7500, Denmark; Recruiting
Solveig Klok Matthesen, Cand. med, Phone: +4599125000, Ext: 5427, Email: cirkussolveig@hotmail.com
Additional Information
Starting date: January 2009
Ending date: November 2010
Last updated: March 6, 2009
|
